| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Recorlev net revenue increased 93% year-over-year to more than $71 million |
| 02 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Experienced biopharmaceutical executive brings global commercial leadership, financial expertise, and public company governance experience |
| 14 Oct 2026 |
8-K: Other Events
On October 13, 2026, Xeris Biopharma Holdings, Inc. (the “Company”), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for the District of New Jersey ... |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure
Copyright © 2021-2026 Xeris Pharmaceuticals, Inc. All rights reserved. Today’s Agenda 2 1 Welcome & Introductions Allison Wey — SVP, Investor Relations 2 Becoming the Next Great Biopharmaceutical Company John Shannon – Chairman and Chief... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Net product revenue increased 34% year-over-year to over $91 million |
| 17 Jul 2026 |
8-K: Unregistered Sales of Equity Securities; Other Events
The information set forth under Item 8.01 below with respect to the Shares (as defined herein) is incorporated into this Item 3.02 by reference, insofar as it relates to the unregistered sales of equity securities. |
| 30 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
CHICAGO, IL – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced... |
| 11 Jun 2026 |
8-K: Unregistered Sales of Equity Securities; Other Events
Eliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings Principal to be paid in cash, remainder in common stock |
| 05 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 14, 2026, the record date for the Annual Meeting, there were 172,62... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Total product revenue increased 43% year-over-year to over $82 million |
| 21 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 20, 2026, Dr. Jeffrey Sherman, a member of the Board of Directors (the “Board”) of Xeris Biopharma Holdings, Inc. (the “Company”), provided notice to the Company of his decision to retire from the Board and not stand for reelect... |
| 02 Mar 2026 |
8-K: Results of Operations and Financial Condition
Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively |
| 27 Feb 2026 |
8-K: Regulation FD Disclosure
CHICAGO, IL; February 26, 2026 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapi... |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition
Anticipates full year 2025 total revenue of $292 million, exceeding the guidance range of $285-$290 million and reflecting growth of 44% compared to the prior year |
| 01 Dec 2025 |
8-K: Regulation FD Disclosure
CHICAGO, IL; December 1, 2025 –Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Updating full-year 2025 total revenue guidance to $285-$290 million; previously $280-$290 million |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Total revenue increased 49% YoY to $71.5 million; Recorlev® revenue grew 136% YoY |
| 04 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2025, Xeris Biopharma Holdings, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 14, 2025, the record date for the Annual Meeting, there were 156,384,578 shares of the Compa... |
| 03 Jun 2025 |
8-K: Regulation FD Disclosure
Copyright © 2021-2025 Xeris Pharmaceuticals, Inc. All rights reserved. Welcome and Agenda Allison Wey SVP, Investor Relations and Corporate Communications 2 |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
Tightens full-year total revenue 2025 guidance to $260 million to $275 million |
Loading...